بدائل البحث:
substantial decrease » substantial increase (توسيع البحث), substantially increased (توسيع البحث)
significant case » significant cause (توسيع البحث), significant based (توسيع البحث), significant change (توسيع البحث)
case based » made based (توسيع البحث), game based (توسيع البحث), rate based (توسيع البحث)
substantial decrease » substantial increase (توسيع البحث), substantially increased (توسيع البحث)
significant case » significant cause (توسيع البحث), significant based (توسيع البحث), significant change (توسيع البحث)
case based » made based (توسيع البحث), game based (توسيع البحث), rate based (توسيع البحث)
-
161
-
162
Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons.
منشور في 2025الموضوعات: -
163
-
164
Deterministic result of the base-case analysis.
منشور في 2024"…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …"
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
The base case analysis.
منشور في 2025"…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …"
-
174
-
175
Base-case results.
منشور في 2025"…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …"
-
176
-
177
-
178
Base-case results.
منشور في 2024"…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …"
-
179
Base-case analysis.
منشور في 2023"…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …"
-
180